 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced it has received 510k marketing clearance from the U.S. Food and Drug Administration FDA for its CarpXTM minimally invasive carpal tunnel device. The FDA determined that CarpX is substantially equivalent to legally marketed predicates and that PAVmed may market CarpX for the minimally invasive isolation and incisiondivision of ligaments, tendons, or fascia such as the transverse carpal ligament for treatment of carpal tunnel syndrome. The FDA reached this determination after reviewing detailed data from the Companys successful CarpX clinical safety study performed in New Zealand. 